| Market Cap | 890.04M | P/E | - | EPS this Y | 32.00% | Ern Qtrly Grth | - |
| Income | -67.06M | Forward P/E | -27.19 | EPS next Y | -13.00% | 50D Avg Chg | -2.00% |
| Sales | 4.09M | PEG | -0.94 | EPS past 5Y | - | 200D Avg Chg | 91.00% |
| Dividend | N/A | Price/Book | 4.44 | EPS next 5Y | 21.70% | 52W High Chg | -13.00% |
| Recommedations | 2.60 | Quick Ratio | 12.46 | Shares Outstanding | 63.29M | 52W Low Chg | 3,763.00% |
| Insider Own | 2.10% | ROA | -18.62% | Shares Float | 21.92M | Beta | - |
| Inst Own | 103.43% | ROE | -37.23% | Shares Shorted/Prior | 1.16M/1.74M | Price | 14.68 |
| Gross Margin | 100.00% | Profit Margin | - | Avg. Volume | 419,328 | Target Price | 28.67 |
| Oper. Margin | -48,350.94% | Earnings Date | - | Volume | 499,565 | Change | -2.52% |
Ambrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology. The company was incorporated in 2003 and is headquartered in La Jolla, California. As of March 7, 2024, Ambrx Biopharma Inc. operates as a subsidiary of Johnson & Johnson.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Nelson Sonja | Chief Financial Offi.. Chief Financial Officer | Oct 27 | Sell | 9.82 | 12,778 | 125,480 | 130,079 | 10/31/23 |
| O'Connor Daniel J. | President and CEO President and CEO | Oct 27 | Sell | 9.82 | 50,012 | 491,118 | 342,845 | 10/31/23 |
| Cormorant Asset Management, LP | 10% Owner 10% Owner | Oct 23 | Buy | 6.9911 | 1,307,311 | 9,139,542 | 11,231,000 | 10/25/23 |
| Cormorant Asset Management, LP | 10% Owner 10% Owner | Sep 15 | Buy | 9.15 | 2,152,738 | 19,697,553 | 69,465,823 | 09/19/23 |
| Cormorant Asset Management, LP | 10% Owner 10% Owner | Apr 18 | Buy | 11.34 | 5,215,189 | 59,140,243 | 67,313,085 | 04/20/23 |
| Cormorant Asset Management, LP | 10% Owner 10% Owner | Apr 13 | Buy | 9.93 | 2,597,896 | 25,797,107 | 62,097,896 | 04/17/23 |